Closing the Gap in Care in Seronegative Inflammatory Arthritis (Metrix II)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Pope Research Corporation
Academic Medical Organization of Southwestern Ontario
Information provided by (Responsible Party):
Pope Research Corporation Identifier:
First received: November 6, 2012
Last updated: May 21, 2013
Last verified: May 2013

Rheumatologists treating patients with seronegative arthritis will be randomized to treat their patients to a target or to treat their patients under their usual standard of care. All physicians will perform an initial chart audit. Following the initial chart audit, all physicians in the treat-to-target group will receive accredited educational training. Six months after the initial chart audit, all physicians will perform a repeat audit to see if patients are assessed more systematically and treated to a target of low disease state.

Condition Intervention
Behavioral: Education and Feedback

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change

Further study details as provided by Pope Research Corporation:

Primary Outcome Measures:
  • Improvement of Systematic Assessments [ Time Frame: November 2012 - November 2013 ] [ Designated as safety issue: No ]
    Physicians in the Education and Feedback arm are assessed via a needs assessment to identify the care gaps for their patients with inflammatory arthritis. After the education and feedback, they complete a second chart audit and their improvements in assessments is recorded.

Estimated Enrollment: 40
Study Start Date: November 2012
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No education or feedback
Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
Experimental: Education and Feedback
Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
Behavioral: Education and Feedback
Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Canadian Rheumatologist

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01749618

Contact: Paul C Tingey, BSc, BEd 519-709-8452

Canada, Ontario
Dr. Vandana Ahluwalia Recruiting
Brampton, Ontario, Canada
Principal Investigator: Vandana Ahluwalia, MD         
Dr. Sanjay Dixit Recruiting
Burlington, Ontario, Canada, L7L 0B7
Principal Investigator: Sanjay Dixit, MD         
Dr Pauline Boulos Recruiting
Hamilton, Ontario, Canada, L8N 1Y2
Principal Investigator: Pauline Boulos, MD         
Dr. Nikhil Chopra Recruiting
London, Ontario, Canada, N6B 2E8
Principal Investigator: Nikhil Chopra, MD         
Credit Valley Rheumatology Recruiting
Mississauga, Ontario, Canada, L5M 2V8
Principal Investigator: Andrew Chow, MD         
Dr Angela Montgomery Recruiting
Mississauga, Ontario, Canada, L5B 2P7
Principal Investigator: Angela Montgomery, MD         
The Medical Centre Not yet recruiting
Peterborough, Ontario, Canada, K9J 7B3
Principal Investigator: Jane Purvis, MD         
Dr. Arthur Karasik Recruiting
Toronto, Ontario, Canada, M9C 5N2
Principal Investigator: Arthur Karasik, MD         
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N 3M5
Principal Investigator: Emily McKeown, MD         
Sponsors and Collaborators
Pope Research Corporation
Academic Medical Organization of Southwestern Ontario
Principal Investigator: Janet E Pope, MD, MPH, FRCPC Pope Research Corp., St. Joseph's Health Care, Western University
  More Information

No publications provided

Responsible Party: Pope Research Corporation Identifier: NCT01749618     History of Changes
Other Study ID Numbers: Metrix II
Study First Received: November 6, 2012
Last Updated: May 21, 2013
Health Authority: Canada: Health Canada

Keywords provided by Pope Research Corporation:
Seronegative Inflammatory Arthritis
Behavioural Change

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases processed this record on October 19, 2014